SciELO - Scientific Electronic Library Online

SciELO - Scientific Electronic Library Online

Referencias del artŪculo

RODRIGO ROYO, M. D.; RIBERA CANUDAS, M. V.; LEDESMA MARTIN-PINTADO, F. ¬†y¬† ZUBILLAGA MARBAN, E.. Razones cl√≠nicas de elecci√≥n de hidromorfona OROS¬ģ para el tratamiento de pacientes con dolor cr√≥nico no oncol√≥gico: Estudio HIDOCO. Rev. Soc. Esp. Dolor [online]. 2012, vol.19, n.3, pp.125-133. ISSN 1134-8046.

    1. Breivik H, Collett B, Ventafridda V, Cohen R, Gallacher D. Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment. Eur J Pain 2006;10(4):287-333. [ Links ]

    2. González-Escalada JR, Barutell A, Camba A, Contreras D, Muriel C, Rodríguez M. Creencias, actitudes y percepciones sw médicos, farmacéuticos y pacientes acerca de la evaluación y el tratamiento del dolor crónico no oncológico. Rev Soc Esp Dolor 2009;16(1):7-20. [ Links ]

    3. Ballantyne JC. Opioid analgesia: perspectives on right use and utility. Pain Physician 2007;10(3):479-91. [ Links ]

    4. Hojsted J, Sjogren P. Addiction to opioids in chronic pain patients: a literature review. Eur J Pain 2007;11(5):490-518. [ Links ]

    5. Noble M, Tregear SJ, Treadwell JR, Schoelles K. Long-term opioid therapy for chronic noncancer pain: a systematic review and meta-analysis of efficacy and safety. J Pain Symptom Manage 2008;35(2):214-28. [ Links ]

    6. Martell BA, O'Connor PG, Kerns RD, Becker WC, Morales KH, Kosten TR, et al. Systematic review: opioid treatment for chronic back pain: prevalence, efficacy, and association with addiction. Ann Intern Med 2007;146(2): 116-27. [ Links ]

    7. Chou R, Clark E, Helfand M. Comparative efficacy and safety of long-acting oral opioids for chronic non-cancer pain: a systematic review. J Pain Symptom Manage 2003;26(5):1026-48. [ Links ]

    8. Kalso E, Edwards JE, Moore RA, McQuay HJ. Opioids in chronic non-cancer pain: systematic review of efficacy and safety. Pain 2004;112(3):372-80. [ Links ]

    9. Furlan AD, Sandoval JA, Mailis-Gagnon A, Tunks E. Opioids for chronic noncancer pain: a meta-analysis of effectiveness and side effects. CMAJ 2006;174(11):1589-94. [ Links ]

    10. Ballantyne JC, Mao J. Opioid therapy for chronic pain. N Engl J Med 2003;349(20):1943-53. [ Links ]

    11. Eisenberg E, McNicol E, Carr DB. Opioids for neuropathic pain. Cochrane Database Syst Rev 2006;3:CD006146. [ Links ]

    12. Deshpande A, Furlan A, Mailis-Gagnon A, Atlas S, Turk D. Opioids for chronic low-back pain. Cochrane Database Syst Rev 2007;(3):CD004959. [ Links ]

    13. Trescot AM, Helm S, Hansen H, Benyamin R, Glaser SE, Adlaka R, et al. Opioids in the management of chronic non-cancer pain: an update of American Society of the Interventional Pain Physicians' (ASIPP) Guidelines. Pain Physician 2008 Mar;11(2 Suppl):S5-S62. [ Links ]

    14. Devulder J, Richarz U, Nataraja SH. Impact of long-term use of opioids on quality of life in patients with chronic, non-malignant pain. Curr Med Res Opin 2005;21(10): 1555-68. [ Links ]

    15. Annemans L. Pharmacoeconomic impact of adverse events of long-term opioid treatment for the management of persistent pain. Clin Drug Investig 2011;31(2):73-86. [ Links ]

    16. Broekmans S, Dobbels F, Milisen K, Morlion B, Vanderschueren S. Medication adherence in patients with chronic non-malignant pain: is there a problem? Eur J Pain 2009;13(2):115-23. [ Links ]

    17. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001;23(8):1296-310. [ Links ]

    18. Ferrell B, Wisdom C, Wenzl C, Brown J. Effects of controlled-released morphine on quality of life for cancer pain. Oncol Nurs Forum 1989;16(4):521-6. [ Links ]

    19. Jurnista® (Summary of Product Characteristics). AEMPS. 2008. 16-11-2010. Ref Type: Online Source [ Links ]

    20. McCarberg BH, Barkin RL. Long-acting opioids for chronic pain: pharmacotherapeutic opportunities to enhance compliance, quality of life, and analgesia. Am J Ther 2001;8(3):181-6. [ Links ]

    21. Wallace M, Skowronski R, Khanna S, Tudor IC, Thipphawong J. Efficacy and safety evaluation of once-daily OROS hydromorphone in patients with chronic low back pain: a pilot open-label study (DO-127). Curr Med Res Opin 2007;23(5):981-9. [ Links ]

    22. Hale M, Tudor IC, Khanna S, Thipphawong J. Efficacy and tolerability of once-daily OROS hydromorphone and twice-daily extended-release oxycodone in patients with chronic, moderate to severe osteoarthritis pain: results of a 6-week, randomized, open-label, noninferiority analysis. Clin Ther 2007;29(5):874-88. [ Links ]

    23. Ringe JD, Djelani MGT. Reduced Need for Acute Medication and Outcomes of Associated Patient-Centred Parameters with OROS® Hydromorphone in Patients with Severe Chronic Osteoporosis and Osteoarthritis. Pain. 2009. [ Links ]

    24. World Medical Association Declaration of Helsinki. Ethical Principles for Medical Research Involving Human Subjects. 2008. Ref Type: Generic [ Links ]

    25. Val JA, Amoros BG, Martinez VP, Fernandez Ferre ML, Leon SM. Descriptive study of patient compliance in pharmacologic antihypertensive treatment and validation of the Morisky and Green test. Aten Primaria 1992;10(5):767-70. [ Links ]

    26. Alonso J, Prieto L, Anto JM. The Spanish version of the SF-36 Health Survey (the SF-36 health questionnaire): an instrument for measuring clinical results. Med Clin (Barc) 1995;104(20):771-6. [ Links ]

    27. Blyth FM, March LM, Brnabic AJ, Jorm LR, Williamson M, Cousins MJ. Chronic pain in Australia: a prevalence study. Pain 2001;89(2-3):127-34. [ Links ]

    28. Elliott AM, Smith BH, Penny KI, Smith WC, Chambers WA. The epidemiology of chronic pain in the community. Lancet 1999;354(9186):1248-52. [ Links ]

    29. Mallen C, Peat G, Thomas E, Croft P. Severely disabling chronic pain in young adults: prevalence from a population-based postal survey in North Staffordshire. BMC Musculoskelet Disord 2005;6:42. [ Links ]

    30. Smith BH, Elliott AM, Chambers WA, Smith WC, Hannaford PC, Penny K. The impact of chronic pain in the community. Fam Pract 2001;18(3):292-9. [ Links ]

    31. Clark JD. Chronic pain prevalence and analgesic prescribing in a general medical population. J Pain Symptom Manage 2002;23(2):131-7. [ Links ]

    32. Carmona L, Ballina J, Gabriel R, Laffon A. The burden of musculoskeletal diseases in the general population of Spain: results from a national survey. Ann Rheum Dis 2001;60(11):1040-5. [ Links ]

    33. Torres LM, Calderón E, Pernia A, Martínez-Vázquez J, Micó JA. De la escalera al ascensor. Rev Soc Esp Dolor 2002;9(5):289-90. [ Links ]

    34. Rodriguez MJ. Valoración de la actitud terapéutica ante el paciente con dolor crónico en las Unidades de Dolor en España. Estudio STEP. Rev Soc Esp Dolor 2006;13(8): 525-32. [ Links ]

    35. Collado F, Torres LM. Asociación de Fentanilo TTS matricial + Citrato de Fentanilo Oral Transmucosa (CFOT), en pacientes que no han recibido tratamiento previo con opioides y padecen dolor crónico intenso de etiología osteoarticular. Haciendo realidad el Ascensor Analgésico. Rev Soc Esp Dolor 2008;14:257-65. [ Links ]

    36. Rubio A, Muñoz E, Sierra R. Anular o acortar los primeros peldaños de la Escalera Analgésica de la OMS. Rev Soc Esp Dolor 2008;15(1):13-20. [ Links ]

    37. Wallace M, Moulin DE, Rauck RL, Khanna S, Tudor IC, Skowronski R, et al. Long-term safety, tolerability, and efficacy of OROS hydromorphone in patients with chronic pain. J Opioid Manag 2009;5(2):97-105. [ Links ]

    38. Noble M, Tregear SJ, Treadwell JR, Schoelles K. Long-term opioid therapy for chronic noncancer pain: a systematic review and meta-analysis of efficacy and safety. J Pain Symptom Manage 2008;35(2):214-28. [ Links ]

    39. Palangio M, Northfelt DW, Portenoy RK, Brookoff D, Doyle RT, Jr., Dornseif BE, et al. Dose conversion and titration with a novel, once-daily, OROS osmotic technology, extended-release hydromorphone formulation in the treatment of chronic malignant or nonmalignant pain. J Pain Symptom Manage 2002;23(5):355-68. [ Links ]

    40. Wallace M, Rauck RL, Moulin D, Thipphawong J, Khanna S, Tudor IC. Once-daily OROS hydromorphone for the management of chronic nonmalignant pain: a dose-conversion and titration study. Int J Clin Pract 2007;61(10): 1671-6. [ Links ]

    41. Wallace M, Rauck RL, Moulin D, Thipphawong J, Khanna S, Tudor IC. Conversion from standard opioid therapy to once-daily oral extended-release hydromorphone in patients with chronic cancer pain. J Int Med Res 2008;36(2):343-52. [ Links ]

    42. Hanna M, Tuca A, Thipphawong J. An open-label, 1-year extension study of the long-term safety and efficacy of once-daily OROS(R) hydromorphone in patients with chronic cancer pain. BMC Palliat Care 2009;8:14. [ Links ]

    43. Hanna M, Thipphawong J. A randomized, double-blind comparison of OROS(R) hydromorphone and controlled-release morphine for the control of chronic cancer pain. BMC Palliat Care 2008;7:17. [ Links ]

    44. Coluzzi F, Mattia C. OROS(R) hydromorphone in chronic pain management: when drug delivery technology matches clinical needs. Minerva Anestesiol 2010;76(12): 1072-84. [ Links ]